Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson’s Disease Model

Figure 10

Different test performed on the different groups was depicted by histograms: (a) narrow beam test; (b) muscle coordination test; (c) forced swim test; (d) grip strength test; (e) akinesia test ( comparison between Group B and other groups). Group A: treated with normal saline via intranasal route; Group B: 6-OHDA induced group treated with normal saline intranasally (PD Model); Group C: 6-OHDA induced group treated with NRG NE intranasally; Group D: 6-OHDA treated lesion group treated with marketed formulation (levodopa) orally; Group E: 6-OHDA treated lesion group treated with NRG NE intranasally along with oral levodopa.

(a)

(b)

(c)

(d)

(e)